Rankings
▼
Calendar
NVAX FY 2023 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$556M
-65.2% YoY
Gross Profit
$213M
38.2% margin
Operating Income
-$567M
-101.8% margin
Net Income
-$545M
-98.0% margin
EPS (Diluted)
$-5.41
Cash Flow
Operating Cash Flow
-$714M
Free Cash Flow
-$773M
Stock-Based Comp.
$85M
Balance Sheet
Total Assets
$1.8B
Total Liabilities
$2.5B
Stockholders' Equity
-$717M
Cash & Equivalents
$569M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$556M
$1.6B
-65.2%
Gross Profit
$213M
$696M
-69.5%
Operating Income
-$567M
-$645M
+12.1%
Net Income
-$545M
-$658M
+17.2%
← Q4 2022
All Quarters
Q1 2023 →